Table 3.
Effect of FRG supplementation on postprandial glucose and insulin levels
| |
Placebo group (n = 21) |
FRG group (n = 21) |
p-
value
2)
|
||||
|---|---|---|---|---|---|---|---|
| Baseline | Week 4 | p- value 1) | Baseline | Week 4 | p- value 1) | ||
| Fasting plasma glucose (mmol/l) |
6.4 ± 0.61 |
6.3 ± 0.6 |
NS |
6.5 ± 0.5 |
6.1 ± 0.6 |
0.039 |
NS |
| Postprandial plasma glucose2h (mmol/l) |
9.0 ± 2.1 |
8.5 ± 1.9 |
NS |
9.3 ± 2.2 |
7.7 ± 1.9 |
0.0001 |
0.008 |
| AUCglucose (mmol/l) |
18.4 ± 0.7 |
17.3 ± 0.7 |
0.045 |
18.6 ± 0.7 |
13.5 ± 1.6 |
0.002 |
0.013 |
| Fasting plasma insulin (μU/ml) |
7.4 ± 0.9 |
6.9 ± 0.6 |
NS |
7.3 ± 1.0 |
9.0 ± 1.3 |
NS |
NS |
| Postprandial plasma insulin2h (μU/ml) | 38.1 ± 3.9 | 35.5 ± 4.1 | NS | 39.2 ± 5.6 | 56.3 ± 9.8 | NS | 0.040 |
1)Analyzed by linear mixed-effect model and the p-value represents the comparison to the baseline visit. 2)Analyzed by linear mixed-effect model and the p-value represents the comparison to the placebo group. Data are presented as the mean ± SEM.